BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, December 9, 2025
Breaking News: Trump administration impacts continue to roil the life sciences sector
See today's BioWorld Science
Home
» Autologous B-cell therapy WFX-001 corrects systemic α-GAL enzyme deficiency in vivo
To read the full story,
subscribe
or
sign in
.
Endocrine/Metabolic
Autologous B-cell therapy WFX-001 corrects systemic α-GAL enzyme deficiency in vivo
Feb. 14, 2024
Walking Fish Therapeutics Inc. presented a new first-in-class autologous B-cell therapy being developed for the treatment of Fabry disease.
BioWorld Science
Conferences
Cell therapy
Endocrine/metabolic
